DDO-8926 is a potent selective inhibitor of bromodomain and extra-terminal (BET) proteins with Ki values of 15 nM (BRD4 BD1) and 9.5 nM (BRD4 BD2).
DDO-8926 showed excellent selectivity over the non-BET bromodomains at 1 uM by the BROMOscan (Eurofins DiscoverX).
DDO-8926 (30 mg/kg, ip) attenuates NP hypersensitivity, regulates genes involved in the generation and transfer of action potentials and inflammatory response.
DDO-8926 reduces microglial and neuronal activation in the spinal cord after SNI and has no effect on astrocytes, alleviates inflammation and affects the expression of ion channels and the Na+/K+ ATPase pump in the spinal cord at 15 dpo after SNI.
